PTC Therapeutics, Inc. PTCT
63.49 USD +0.13 (+0.21%)
At closeNov 13, 2026, 4:00 PM EST
63.49 0.00 0.00%
After hours · Nov 13, 4:00 PM ET
62.51 Day range 63.74
59.24 52-week range 89.55
- YTD
- -16.42%
- 1 year
- -15.29%
News
benzinga.com PTC Therapeutics Board Authorizes $500M Share Repurchase Program PTC Therapeutics, Inc., (NASDAQ:PTCT) today announced that its Board of Directors has authorized a share repurchase program under which PTC may repurchase up to $500 million of the Company's…
benzinga.com Citigroup Maintains Buy on PTC Therapeutics, Raises Price Target to $109 Citigroup analyst Eric Joseph maintains PTC Therapeutics (NASDAQ:PTCT) with a Buy and raises the price target from $108 to $109.- benzinga.com TD Cowen Maintains Buy on PTC Therapeutics, Raises Price Target to $95 TD Cowen analyst Joseph Thome maintains PTC Therapeutics (NASDAQ:PTCT) with a Buy and raises the price target from $90 to $95.
- benzinga.com RBC Capital Maintains Sector Perform on PTC Therapeutics, Raises Price Target to $77 RBC Capital analyst Brian Abrahams maintains PTC Therapeutics (NASDAQ:PTCT) with a Sector Perform and raises the price target from $75 to $77.
benzinga.com Wells Fargo Maintains Overweight on PTC Therapeutics, Raises Price Target to $112 Wells Fargo analyst Benjamin Burnett maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and raises the price target from $109 to $112.
benzinga.com PTC Therapeutics Q3 2026 Earnings Call Transcript PTC Therapeutics (NASDAQ:PTCT) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought…
benzinga.com CORRECTION: PTC Therapeutics Q3 Adj. EPS $0.94 Beats $0.34 Estimate, Sales $357.807M Beat $306.399M Estimate PTC Therapeutics (NASDAQ:PTCT) reported quarterly earnings of $0.94 per share which beat the analyst consensus estimate of $0.34 by 176.47 percent. This is a 370 percent increase over earnings of…
benzinga.com PTC Therapeutics Raises FY2026 Sales Guidance from $1.180B-$1.280B to $1.290B-$1.320B vs $1.262B Est PTC Therapeutics (NASDAQ:PTCT) raises FY2026 sales outlook from $1.180 billion-$1.280 billion to $1.290 billion-$1.320 billion vs $1.262 billion estimate.